Screening for prostate cancer with PSA testing: Current status and future directions

Oncology

Volumn 25, Issue 6, 2011, Pages

  Croswell, Jennifer M ^a   Kramer, Barnett S ^b   Crawford, E David ^c  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CLINICAL STUDY; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; HEALTH SURVEY; HUMAN; INTERMETHOD COMPARISON; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PROSTATE CANCER; RISK BENEFIT ANALYSIS;

EID: 79956345344     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Society AC. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.
2. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003;16:95-101.
3. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (Clinical research ed). 2010;341:c4543.
4. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66-70.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239-46.
6. CDC. Surveillance for certain health behaviors among states and selected local areasUnited States, 2008. Atlanta, 2010. [cited 2011 Jan 13]; 59(SS-10)] Available from: http://www.cdc.gov/mmwr/pdf/ss/ss5910.pdf.
7. Farkas A, Schneider D, Perrotti M, et al. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology. 1998;52:444-8; discussion 8-9.
8. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008;9:445-52.
9. Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol. 1999;161:529-33.
10. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417-24.
11. Marcella SW, Rhoads GG, Carson JL, et al. Prostate-specific antigen screening and mortality from prostate cancer. J Gen Intern Med. 2008;23:248-53.
12. Lu-Yao G, Albertsen PC, Stanford JL, et al. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med. 2008;23:1809-14.
13. Perron L, Moore L, Bairati I, et al. PSA screening and prostate cancer mortality. CMAJ. 2002;166:586-91.
14. Orde MM, Whitaker NJ, Lawson JS. High prevalence of prostatic neoplasia in Australian men. Pathology. 2009;41:433-5.
15. Stamatiou K, Alevizos A, Agapitos E, Sofras F. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study. Prostate. 2006;66:1319-28.
16. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. Ann Intern Med. 1997;126:394-406.
17. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150:379-85.
18. Welch HG, Black WC. Overdiagnosis in cancer. Journal of the National Cancer Institute.102:605-13.
19. SEER*Stat Database: Incidence - SEER 9 Regs Limited-Use, Nov 2008 Sub (1973-2006) - Linked To County Attributes - Total U.S., 1969-2006 Counties; National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; released April 2009, based on the November 2008 submission. Available at www.seer.cancer.gov.
20. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. JNCI. 2009;101:1325-9.
21. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59:311-8.
22. Sandblom G, Varenhorst E, Lofman O, et al. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004;46:717-23; discussion 24.
23. Kjellman A, Akre O, Norming U, et al. 15-year follow-up of a population based prostate cancer screening study. J Urol. 2009;181:1615-21; discussion 21.
24. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9.
25. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8.
26. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol.11:725-32.
27. Barry MJ. Screening for prostate cancerthe controversy that refuses to die. N Engl J Med. 2009;360:1351-4.
28. Tornblom M, Eriksson H, Franzen S, et al. Lead time associated with screening for prostate cancer. Int J Cancer. 2004;108:122-9.
29. Roobol MJ, Kerkhof M, Schroder FH, et al. Prostate cancer mortality reduction by prostate-specific antigenbased screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2009;56:584-91.
30. Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. JNCI. 2007;99:1296-303.
31. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer.126:2387-93.
32. Boevee SJ, Venderbos LD, Tammela TL, et al. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. Eur J Cancer.46:3082-9.
33. Croswell JM, Kramer BS, Kreimer AR, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009;7:212-22.
34. Kilpelainen TP, Tammela TL, Maattanen L, et al. False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer.102:469-74.
35. McNaughton-Collins M, Fowler FJ, Jr., Caubet JF, et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med. 2004;117:719-25.
36. Fowler FJ, Jr., Barry MJ, Walker-Corkery B, et al. The impact of a suspicious prostate biopsy on patients psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med. 2006;21:715-21.
37. Rietbergen JB, Kruger AE, Kranse R, Schroder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology. 1997;49:875-80.
38. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-61.
39. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. JNCI. 2004;96:1358-67.
40. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993; 269:2633-6.
41. Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. JNCI. 2005;97:1525-32.
42. Yao SL, Lu-Yao G. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. JNCI. 1999;91:1950-6.
43. Kilpelainen TP, Tammela TL, Maattanen L, et al. False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer. 2010;102:469-74.
44. Bangma CH, van Schaik RH, Blijenberg BG, et al. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. Eur J Cancer.46:3109-19.
45. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Rev. 2008;8:268-78.
46. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA: Cancer J Clin. 2010;60:70-98.
47. Kawachi M, et al. NCCN Clinical practice guidelines in oncology: prostate cancer, version 2.2010. 2010. [cited 2011 January 11] Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf.
48. Carrol P, et al. American Urological Assocation prostate-specific antigen best practice statement: 2009 update. 2009 [updated January 11, 2011]. Available from: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf.
49. Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001;58:411-6.
50. Ransohoff DF, McNaughton Collins M, Fowler FJ. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med. 2002;113:663-7.
51. Black WC, Welch HG. Screening for disease. AJR. 1997;168:3-11.
52. Albin RJ. The great prostate mistake. New York Times. March 10, 2010.
53. American Academy of Family Physicians. Policies for clinical preventive services: prostate cancer. 2008. [cited 2011 January 11] Available from: http://www.aafp.org/online/en/home/clinical/exam/prostatecancer.html.
54. Lim LS, Sherin K. Screening for prostate cancer in US men. ACPM position statement on preventive practice. Am J Prev Med. 2008;34:164-70.
55. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185-91.